Kymriah Injection, Suspension
Product Images NDC 0078-0958

3 FDA label images from Novartis Pharmaceuticals Corporation · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Kymriah (NDC 0078-0958). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Note: The Patient Identifier Number May Be Preceded By The Letters Din Or Aph Id. Figure 1. Kymriah Infusion Bag (Kymriah 01)

Note: The Patient Identifier Number May Be Preceded By The Letters Din Or Aph Id. Figure 1. Kymriah Infusion Bag (Kymriah 01)
Illustration showing a labeled bag for KYMRIAH (tisagenlecleucel) cellular therapy injection, suspension for intravenous use. The image highlights the label area with patient information fields including Name, Date of Birth, DIN or Aph ID, Expiry Date, Batch number, and Material numbers. The bag is marked with the Novartis logo.*
FDA Label Image

Principal Display Panel Tisagenlecleucel Kymriah® Ndc 0078-0958-19 Human T Cells Rx Only Suspension For Iv Infusion Cultured, Genetically Modified For Autologous Use Only Dispense With Medication Guide Novartis (Kymriah 03)

Principal Display Panel								Tisagenlecleucel								Kymriah®								Ndc 0078-0958-19								Human T Cells								Rx Only 								Suspension For Iv Infusion								Cultured, Genetically Modified								For Autologous Use Only								Dispense With Medication Guide								Novartis (Kymriah 03)
Label for KYMRIAH (tisagenlecleucel) injection, suspension for intravenous infusion. The label describes it as a human T cell suspension, genetically modified for autologous use only. It includes dosage form details, storage instructions at or below -120°C, manufacturer information (Novartis Pharmaceuticals Corporation), and contact information.*
FDA Label Image

Principal Display Panel Tisagenlecleucel Kymriah® Ndc 0078-0846-19 Human T Cells Rx Only Suspension For Iv Infusion Cultured, Genetically Modified For Autologous Use Only Dispense With Medication Guide Novartis (Kymriah 02)

Principal Display Panel								Tisagenlecleucel								Kymriah®								Ndc 0078-0846-19								Human T Cells								Rx Only 								Suspension For Iv Infusion								Cultured, Genetically Modified								For Autologous Use Only								Dispense With Medication Guide								Novartis (Kymriah 02)
Label for KYMRIAH injection, suspension containing tisagenlecleucel, a cellular therapy for intravenous infusion. The label indicates it contains cultured, genetically modified human T cells for autologous use only. It lists storage instructions at or below -120°C and manufacturer as Novartis Pharmaceuticals Corporation, Morris Plains, NJ. Dosage and preparation details are included, along with a barcode and contact information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.